Press Release: Press Release: Cebit 2017: Computational Biologists Predict Antibiotic Resistances Using Biotech

Curetis / Press Release: Cebit 2017: Computational Biologists Predict Antibiotic Resistances Using Biotech . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Every year, some 25,000 people die in the European Union from antibiotic-resistant, hard to treat bacteria. Although there are diagnostic methods in place to recognize such resistances in advance, these are typically very time-consuming. Researchers from the Center for Bioinformatics at Saarland University, in cooperation with the molecular diagnostics company Curetis, are developing techniques to uncover these dangerous resistances a lot faster. Their secret weapons: a comprehensive gene database, and powerful algorithms. The researchers will be presenting their rapid test procedures, and their outlook for the future, at Stand E28 at the Cebit computer trade show in Hannover, Germany.

Just a few days ago, the World Health Organization (WHO) published a list of twelve antibiotic-resistant bacterial strains, which are considered to be the "greatest threats to human health".

Andreas Keller, professor for Clinical Bioinformatics at Saarland University, is also studying these bacterial resistances. "If a patient receives faster access to the treatment best suited to fight the disease in question, it is not only to the benefit of the patient. It also helps dispensing currently available antibiotics in a more targeted manner, so that the development of resistances can be slowed down," Keller explains.

Existing methods to uncover these resistances in bacterial strains are very time-consuming. First the bacteria are grown in Petri dish nutrient solutions. Once a culture is visible, its response to antibiotics can be tested. But until the result is conclusive, the patient's precious time goes by. "It can take some 24 to 72 hours for the doctor to know for sure which antibiotic to use for the respective treatment. But medical professionals will rarely let a patient suffer for that long, so they tend to rely on their experience," says the Chief Commercial Officer of Curetis, Achim Plum. "It's not much use to patients, if doctors pick the wrong antibiotics. What is more, with every antibiotic use, the risk of generating resistant pathogens is increased. And since bacteria multiply very quickly, this is like evolution in time lapse," says Plum. The company from Southern Germany already offers rapid-test procedures with specialized molecules that detect pathogens, and their specific resistances, for various conditions including pulmonary infections, tissue and transplant infections, and infections of the blood or abdominal cavity. Plum: "We are currently using genetic markers for antibiotic resistances that have been known for a while. In this manner we can cover the most common resistance mechanisms. But we are also aware that there are still resistances that elude us. This is why we are also trying to decipher those mechanisms that may be uncommon at present, but could become a major threat in future. But in order to develop more efficient test procedures, we need studies of hundreds or thousands of pathogens that have been isolated from patients. We are looking for the complete genetic information of pathogens, as well as their response to common antibiotics, so that we can establish links between antibiotic resistances and the genetic changes that prompted them."

For this purpose, Curetis acquired the genetic library GEAR ("Genetic Antibiotic Resistance and Susceptibility") from the Siemens Technology Accelerator in September 2016. The database and associated platform were developed in collaboration with two universities: The Institute of Clinical Molecular Biology in Kiel was responsible for bacterial gene sequencing, while Andreas Keller and his working group on Clinical Bioinformatics at Saarland University focused on the computer-aided data analysis of the 30-terabyte database.

"Bacteria are uncannily clever, and very quick to act upon their genetic predispositions for resistance. Thanks to GEAR, we can now better understand their individual strategies," says computational biologist Andreas Keller. The foundation of this genetic library is a global database comprising several decades' worth of information. Currently GEAR contains data on 11,000 bacterial strains, isolated from patient samples from all over the world over the past thirty years, and their respective reaction patterns to 21 common antibiotics.

With the help of this data, researchers can examine genetic abnormalities associated with certain antibiotic resistances. "It's like a gigantic puzzle," Keller says, and quickly extrapolates that the data collected is equivalent to about 500,000 Bibles. But his algorithms and first results give him confidence: "We can already accurately predict resistances 85 percent of the time."

Resistances develop dynamically, no matter how common or novel the antibiotic in question is. So the GEAR database needs to be adaptable in future as well. "Antibiotic resistance is one of the most urgent health care problems in the world, and research should be well-coordinated. We are planning to expand GEAR into a joint research platform for antibiotic resistances, helping to close the ranks between academic research, public healthcare, and health industry," says Achim Plum.

Additional Information:

Press photos available here: www.uni-saarland.de/pressefotos

Caption:

Time-consuming: Bacteria have to be cultivated in nutrient media in order to detect resistances. Special tests and gene data are designed to provide faster and more reliable results.

Further Inquiries:

Professor Andreas Keller

Chair of Clinical Bioinformatics

Saarland University

Phone: +49 681 302 68611

E-Mail: andreas.keller@ccb.uni-saarland.de

Dr Achim Plum

Managing Director

Curetis GmbH

Phone: +49 7031 49195 65

E-Mail: achim.plum@curetis.com

Editor:

Gordon Bolduan

Competence Center Computer Science Saarland

Saarland Informatics Campus E1.7

Saarland University

Phone: +49 681 302-70741

E-Mail: bolduan@mmci.uni-saarland.de

Media and Investor Inquiries Regarding Curetis:

akampion

Dr. Ludger Wess & Ines-Regina Buth

Managing Partners

info(@)akampion.com

Phone +49 40 88 16 59 64

Phone +49 30 23 63 27 6

Background: Saarland Informatics Campus

The Department of Computer Science at Saarland University represents the heart of the Saarland Informatics Campus. Seven other internationally renowned research institutes are nearby: The Max Planck Institutes for Informatics and for Software Systems, the German Research Center for Artificial Intelligence (DFKI), the Center for Bioinformatics, the Intel Visual Computing Institute, the Center for IT Security, Privacy and Accountability (CISPA), and the Cluster of Excellence "Multimodal Computing and Interaction".

About Curetis

Curetis (www.curetis.com) is a molecular diagnostics company founded in 2007, focusing on the development and commercialization of reliable, rapid and cost-effective products for the diagnostics of infectious diseases. Curetis' diagnostic solutions allow for faster identification of pathogens and antibiotic resistance gene markers in a matter of hours. Other currently available techniques need days or even weeks. The company is based in Holzgerlingen near Stuttgart.

For further information, please visit www.curetis.com.

Legal Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.

The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

20170310_PR_Curetis_EN: http://hugin.info/171382/R/2086878/787463.pdf Curetis_logo http://hugin.info/171382/R/2086878/787464.jpg

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Curetis via Globenewswire

--- End of Message ---

Curetis

Max-Eyth-Str. 42 Holzgerlingen Germany

Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;

http://www.curetis.com/ (END) Dow Jones Newswires

   March 10, 2017 06:47 ET (11:47 GMT)- - 06 47 AM EST 03-10-17